Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alemtuzumab.

Farhad Ravandi1, Susan O'Brien

  • 1Department of Leukemia, University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd., Houston, TX 77030-4095, USA. fravandi@mdanderson.org

Expert Review of Anticancer Therapy
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Cancer·2019
Same author

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood cancer journal·2019
Same author

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Nature communications·2019
Same author

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2019
Same author

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Journal of hematology & oncology·2019
Same author

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

The Lancet. Haematology·2018
Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026
Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026
Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026
See all related articles

Alemtuzumab, an antibody targeting CD52, shows clinical activity in various blood cancers and graft-versus-host disease. With infection management, its therapeutic uses are expected to expand.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Alemtuzumab is a monoclonal antibody targeting the CD52 glycoprotein.
  • CD52 is highly expressed on lymphocytes but not hematopoietic progenitor cells.

Purpose of the Study:

  • To review the clinical applications of alemtuzumab.
  • To discuss its efficacy in hematologic malignancies and graft-versus-host disease.
  • To explore potential future applications in autoimmune disorders.

Main Methods:

  • Clinical trial data review.
  • Analysis of alemtuzumab's mechanism of action.
  • Assessment of safety profile, particularly infections.

Main Results:

  • Alemtuzumab demonstrates clinical activity in chronic lymphocytic leukemia and T-cell malignancies.

Related Experiment Videos

  • It is effective in preventing and treating graft-versus-host disease post-transplant.
  • Profound lymphopenia leading to infections is the primary side effect.

    • Conclusions:

    • Alemtuzumab is a valuable therapeutic agent in hematologic oncology and transplantation.
    • Careful management of infections with prophylaxis can mitigate risks.
    • Expanded use in autoimmune diseases is anticipated.